Centene Corporation: Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Centene Corporation is a leading healthcare enterprise providing managed care services primarily through government-sponsored programs (Medicaid, Medicare) and the Health Insurance Marketplace. As of June 30, 2025, the company reported total managed care membership of 28.0 million, a decrease of 2% year-over-year, driven by Medicaid redeterminations and strategic exits in certain Medicare Advantage markets, partially offset by significant growth in Medicare Prescription Drug Plans (PDP) and Marketplace membership.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Total Revenues | $48.7 billion | $39.8 billion | $95.4 billion | $80.2 billion |
| Premium & Service Revenues | $42.5 billion | $36.0 billion | $85.0 billion | $72.3 billion |
| Net Earnings (Loss) Attributable to Centene | $(253) million | $1,146 million | $1,058 million | $2,309 million |
| Diluted EPS (GAAP) | $(0.51) | $2.16 | $2.13 | $4.32 |
| Adjusted Diluted EPS | $(0.16) | $2.42 | $2.75 | $4.68 |
| Health Benefits Ratio (HBR) | 93.0% | 87.6% | 90.2% | 87.3% |
| SG&A Expense Ratio | 7.1% | 8.0% | 7.5% | 8.5% |
| Cash and Cash Equivalents | $14.5 billion | $17.6 billion | $14.5 billion | $17.6 billion |
| Total Debt | $17.6 billion | $18.5 billion | $17.6 billion | $18.5 billion |
Material Changes vs. Prior Period
- Profitability Decline: The company reported a GAAP net loss of $253 million for Q2 2025, compared to net earnings of $1.1 billion in Q2 2024. This reversal was primarily driven by a reduction in the estimated net 2025 Marketplace risk adjustment revenue transfer and increased medical costs.
- Revenue Growth: Total revenues increased 22% year-over-year to $48.7 billion, fueled by a 58% revenue increase in the Medicare segment (driven by PDP growth) and a 16% increase in the Medicaid segment (driven by rate increases).
- Margin Compression: The Health Benefits Ratio (HBR) deteriorated to 93.0% from 87.6% in the prior year. Key drivers included higher medical costs in Medicaid (behavioral health, home health, high-cost drugs), increased Marketplace medical costs, and a $389 million increase in the Medicare Advantage premium deficiency reserve.
- Impairment Charges: The company recorded $55 million in impairment charges related to the wind-down of certain contracts in the "Other" segment, compared to no impairment in Q2 2024.
- Membership Shifts: While total membership declined slightly, the mix shifted significantly. PDP membership grew 19% year-over-year, and Marketplace membership grew 33%, while Medicare Advantage membership declined 10% due to strategic positioning.
Guidance, Outlook, and Risks
- Regulatory Impact (OBBBA): The "One Big Beautiful Bill Act" (OBBBA), passed in July 2025, introduces work requirements and cost-sharing for Medicaid expansion members and restricts Advance Premium Tax Credits (APTCs) for Marketplace enrollees. Management anticipates these changes will reduce 2026 Marketplace membership and increase population morbidity.
- Medical Cost Trends: The company is experiencing an accelerated increase in medical cost trends due to high-cost pharmaceuticals and expanded access to care. Management is refiling 2026 policy year rates to reflect higher projected morbidity.
- Legal Proceedings: A putative federal securities class action was filed on July 9, 2025, alleging false statements regarding 2025 earnings guidance. The company denies wrongdoing and is vigorously defending the claim.
- Subsequent Events: Due to market conditions and the OBBBA, the company plans to perform a quantitative impairment analysis on goodwill and intangibles, which may result in future impairment charges.
- Liquidity: The company maintains a strong liquidity position with $14.5 billion in cash and cash equivalents and $4.0 billion available under its Revolving Credit Facility. It expects available resources to be sufficient for operations for at least 12 months.
Investor Verification Checklist
- Risk Adjustment Estimates: Verify the methodology and assumptions behind the reduced 2025 Marketplace risk adjustment revenue transfer, which significantly impacted Q2 earnings.
- Premium Deficiency Reserves: Monitor the progression of the Medicare Advantage premium deficiency reserve, which increased to $389 million in Q2 2025 and is expected to be released in Q4 2025.
- Medical Cost Trends: Assess the sustainability of the 93.0% HBR and the effectiveness of new clinical initiatives in curbing rising costs in behavioral health and specialty drugs.
- Regulatory Compliance: Track the impact of the OBBBA and the Marketplace Integrity & Affordability Final Rule on 2026 enrollment projections and pricing strategies.
- Legal Exposure: Monitor the status of the July 2025 securities class action and potential outcomes of ongoing Medicaid contract protests in Georgia and Texas.